Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2009-10-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Propranolol
Propranolol
40 mg
Propranolol ER
120 mg twice per day
Sugar pill
Sugar pills
sugar pill
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propranolol
40 mg
Propranolol ER
120 mg twice per day
Sugar pills
sugar pill
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ages 18-60 yrs
* pain score \>= 4
* speak and read English
Exclusion Criteria
* paraplegia/quadriplegia
* pregnancy
* psychotic, suicidal, or homicidal
* hepatic, kidney failure
* clinically unstable or intubated at time of recruitment
* hyperthyroidism
* propranolol use within the last 6 months
* significant bradycardia
* cancer (except basal cell)
* peripheral vascular disease
* heart block \> 1 degree
* breastfeeding
* congestive heart failure
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of North Carolina, Chapel Hill
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samuel McLean, MD
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samuel M McLean, MD MPH
Role: PRINCIPAL_INVESTIGATOR
UNC Chapel Hill School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of North Carolina Trauma Center
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-1391
Identifier Type: -
Identifier Source: org_study_id